Search results
Jul 18, 2024 · Crinetics is a pharmaceutical company that develops much-needed therapies for people with endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives.
Crinetics was founded by a team of scientists in drug discovery and development who are dedicated to creating new therapies for rare endocrine disease patients.
Crinetics Pharmaceuticals (CRNX) Investor Relations – Press releases, events, financials / SEC filings, corporate governance, FAQ, stock quote chart, contact information for stock holders, financial analysts, and investors.
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and...
Get the latest Crinetics Pharmaceuticals Inc (CRNX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...
Crinetics Pharmaceuticals | 17,083 followers on LinkedIn. Discovering drugs for endocrine diseases and endocrine-related tumors. #acromegaly #crinetics #CarcinoidSyndrome | This place is about ...
Sep 11, 2023 · Sept 11 (Reuters) - Shares of drug developer Crinetics Pharmaceuticals (CRNX.O) jumped about 72% on Monday after its experimental treatment for a rare hormonal disorder not only succeeded, but...
Jul 10, 2024 · Get a real-time Crinetics Pharmaceuticals, Inc. (CRNX) stock price quote with breaking news, financials, statistics, charts and more.
Mar 19, 2024 · SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced positive topline results from PATHFNDR-2, the second of two Pha...
Crinetics Pharmaceuticals (CRNX) Investor Relations – Press releases, events, financials / SEC filings, corporate governance, FAQ, stock quote chart, contact information for stock holders, financial analysts, and investors.
